Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
BlackRock lifts AB InBev stake to 3.25% voting rights

BlackRock lifts AB InBev stake to 3.25% voting rights

ReutersReuters2026/09/03 05:05
  • BlackRock lifted its stake in AB InBev above the 3% threshold on Sept. 1, reaching 3.25% of voting rights.
  • The position comprised 62,956,665 voting rights from shares, equal to 3.12%.
  • Equivalent financial instruments added 2,747,556 potential voting rights, equal to 0.14%.
  • The holding whipsawed around 3% in late August, dipping to 2.99% on Aug. 26 and Aug. 31.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB - Anheuser-Busch InBev SA published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S602658), on September 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

German factory orders exceed expectations for three consecutive months, signaling a gradual economic recovery

Data released by the German Federal Statistical Office on Thursday showed that factory orders increased by 2.5% month-on-month in July. The figure for June was revised upwards to a 3.7% increase.

智通财经2026/09/04 07:36
German factory orders exceed expectations for three consecutive months, signaling a gradual economic recovery

Roche (RHHBY.US) Vamixibai monoclonal antibody injection's marketing application accepted by CDE for the treatment of uveitic macular edema

According to the official website of the CDE, the marketing application for Roche (RHHBY.US) Vamiki bai monoclonal antibody injection has been accepted.

智通财经2026/09/04 07:31
Roche (RHHBY.US) Vamixibai monoclonal antibody injection's marketing application accepted by CDE for the treatment of uveitic macular edema